190 related articles for article (PubMed ID: 25443793)
1. Diagnosis and treatment of hereditary tyrosinemia in Japan.
Nakamura K; Matsumoto S; Mitsubuchi H; Endo F
Pediatr Int; 2015; 57(1):37-40. PubMed ID: 25443793
[TBL] [Abstract][Full Text] [Related]
2. Hereditary tyrosinemia type Ⅰ: newborn screening, diagnosis and treatment.
Tang Y; Kong Y
Zhejiang Da Xue Xue Bao Yi Xue Ban; 2021 Aug; 50(4):514-523. PubMed ID: 34704422
[TBL] [Abstract][Full Text] [Related]
3. Hereditary tyrosinemia type 1 in Turkey: twenty year single-center experience.
Zeybek AC; Kiykim E; Soyucen E; Cansever S; Altay S; Zubarioglu T; Erkan T; Aydin A
Pediatr Int; 2015 Apr; 57(2):281-9. PubMed ID: 25223216
[TBL] [Abstract][Full Text] [Related]
4. Type 1 tyrosinemia in Finland: a nationwide study.
Äärelä L; Hiltunen P; Soini T; Vuorela N; Huhtala H; Nevalainen PI; Heikinheimo M; Kivelä L; Kurppa K
Orphanet J Rare Dis; 2020 Oct; 15(1):281. PubMed ID: 33046095
[TBL] [Abstract][Full Text] [Related]
5. Effect of nitisinone (NTBC) treatment on the clinical course of hepatorenal tyrosinemia in Québec.
Larochelle J; Alvarez F; Bussières JF; Chevalier I; Dallaire L; Dubois J; Faucher F; Fenyves D; Goodyer P; Grenier A; Holme E; Laframboise R; Lambert M; Lindstedt S; Maranda B; Melançon S; Merouani A; Mitchell J; Parizeault G; Pelletier L; Phan V; Rinaldo P; Scott CR; Scriver C; Mitchell GA
Mol Genet Metab; 2012 Sep; 107(1-2):49-54. PubMed ID: 22885033
[TBL] [Abstract][Full Text] [Related]
6. [Application of succinylacetone levels measurement in the blood and urine in the diagnosis of tyrosinemia type 1].
Han LS; Ye J; Qiu WJ; Zhang HW; Wang Y; Ji WJ; Gao XL; Li XY; Jin J; Gu XF
Zhonghua Er Ke Za Zhi; 2012 Feb; 50(2):126-30. PubMed ID: 22455637
[TBL] [Abstract][Full Text] [Related]
7. Tyrosinemia type 1 in Spain: mutational analysis, treatment and long-term outcome.
Couce ML; Dalmau J; del Toro M; Pintos-Morell G; Aldámiz-Echevarría L;
Pediatr Int; 2011 Dec; 53(6):985-9. PubMed ID: 21752152
[TBL] [Abstract][Full Text] [Related]
8. Nitisinone: new drug. Type 1 tyrosinemia: an effective drug.
Prescrire Int; 2007 Apr; 16(88):56-8. PubMed ID: 17458044
[TBL] [Abstract][Full Text] [Related]
9. Hereditary Tyrosinemia Type 1 in Turkey.
Aktuglu-Zeybek AC; Kiykim E; Cansever MS
Adv Exp Med Biol; 2017; 959():157-172. PubMed ID: 28755194
[TBL] [Abstract][Full Text] [Related]
10. Hepatocellular carcinoma requiring liver transplantation in hereditary tyrosinemia type 1 despite nitisinone therapy and α1-fetoprotein normalization.
Bhushan S; Noble C; Balouch F; Lewindon P; Lampe G; Hodgkinson P; McGill J; Ee L
Pediatr Transplant; 2022 Nov; 26(7):e14334. PubMed ID: 35698261
[TBL] [Abstract][Full Text] [Related]
11. Tyrosinemia type I: clinical and biochemical analysis of patients in Mexico.
Fernández-Lainez C; Ibarra-González I; Belmont-Martínez L; Monroy-Santoyo S; Guillén-López S; Vela-Amieva M
Ann Hepatol; 2014; 13(2):265-72. PubMed ID: 24552869
[TBL] [Abstract][Full Text] [Related]
12. Laboratory monitoring of patients with hereditary tyrosinemia type I.
Schultz MJ; Netzel BC; Singh RH; Pino GB; Gavrilov DK; Oglesbee D; Raymond KM; Rinaldo P; Tortorelli S; Smith WE; Matern D
Mol Genet Metab; 2020 Aug; 130(4):247-254. PubMed ID: 32546364
[TBL] [Abstract][Full Text] [Related]
13. The genetic tyrosinemias.
Scott CR
Am J Med Genet C Semin Med Genet; 2006 May; 142C(2):121-6. PubMed ID: 16602095
[TBL] [Abstract][Full Text] [Related]
14. Diagnostic and Therapeutic Challenges of Hereditary Tyrosinemia Type 1 in Lebanon: A 12-Year Retrospective Review.
Daou KN; Barhoumi A; Bassyouni A; Karam PE
Front Pediatr; 2021; 9():698577. PubMed ID: 34422723
[No Abstract] [Full Text] [Related]
15. Evaluation of pre-symptomatic nitisinone treatment on long-term outcomes in Tyrosinemia type 1 patients: a systematic review.
Geppert J; Stinton C; Freeman K; Fraser H; Clarke A; Johnson S; Sutcliffe P; Taylor-Phillips S
Orphanet J Rare Dis; 2017 Sep; 12(1):154. PubMed ID: 28893311
[TBL] [Abstract][Full Text] [Related]
16. Clinical utilization of dried blood spot nitisinone (NTBC) and succinylacetone (SA) concentrations in hereditary tyrosinaemia type 1 - A UK centre experience.
Yeo M; Turner C; Dalton NR; Rahman Y; Vara R
Ann Clin Biochem; 2020 Nov; 57(6):412-419. PubMed ID: 32936663
[TBL] [Abstract][Full Text] [Related]
17. Clinical utility of nitisinone for the treatment of hereditary tyrosinemia type-1 (HT-1).
Das AM
Appl Clin Genet; 2017; 10():43-48. PubMed ID: 28769581
[TBL] [Abstract][Full Text] [Related]
18. Improved method to determine succinylacetone in dried blood spots for diagnosis of tyrosinemia type 1 using UPLC-MS/MS.
Al-Dirbashi OY; Rashed MS; Jacob M; Al-Ahaideb LY; Al-Amoudi M; Rahbeeni Z; Al-Sayed MM; Al-Hassnan Z; Al-Owain M; Al-Zeidan H
Biomed Chromatogr; 2008 Nov; 22(11):1181-5. PubMed ID: 18651606
[TBL] [Abstract][Full Text] [Related]
19. Diagnosis and treatment of tyrosinemia type I: a US and Canadian consensus group review and recommendations.
Chinsky JM; Singh R; Ficicioglu C; van Karnebeek CDM; Grompe M; Mitchell G; Waisbren SE; Gucsavas-Calikoglu M; Wasserstein MP; Coakley K; Scott CR
Genet Med; 2017 Dec; 19(12):. PubMed ID: 28771246
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
